Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials
BMC Pregnancy and Childbirth, 03/16/2012Schuit E et al.
Individual studies have not had sufficient power to evaluate potential benefits in women at particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to determine adverse effects for rare outcomes such as intrauterine death.
The authors propose an individual participant data meta–analysis of high quality randomized, double–blind, placebo–controlled trials of progestogen treatment in women with a twin pregnancy.
The primary outcome will be adverse perinatal outcome (a composite measure of perinatal mortality and significant neonatal morbidity).
Missing data will be imputed within each original study, before data of the individual studies are pooled.
The effects of 17–hydroxyprogesterone caproate or vaginal progesterone treatment in women with twin pregnancies will be estimated by means of a random effects log–binomial model.
Analyses will be adjusted for variables used in stratified randomization as appropriate.
Pre–specified subgroup analysis will be performed to explore the effect of progestogen treatment in high–risk groups.
Combining individual patient data from different randomized trials has potential to provide valuable, clinically useful information regarding the benefits and potential harms of progestogens in women with twin pregnancy overall and in relevant subgroups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.